DDrare: Database of Drug Development for Rare Diseases

Topical infliximab (DrugBank: Infliximab)

3 diseases

ID	Disease name (Link within this page)	Number of trials
38	Stevens-Johnson syndrome	1
39	Toxic epidermal necrolysis	1
162	Pemphigoid	1

38. Stevens-Johnson syndrome [ 11 clinical trials, 19 drugs, (DrugBank: 8 drugs), 14 drug target genes, 98 drug target pathways]

Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 11 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada

39. Toxic epidermal necrolysis [ 11 clinical trials, 18 drugs, (DrugBank: 8 drugs), 11 drug target genes, 101 drug target pathways]

Searched query = "Toxic epidermal necrolysis", "Toxic epidermal necrosis", "TEN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 11 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada

162. Pemphigoid [ 70 clinical trials, 117 drugs, (DrugBank: 46 drugs), 30 drug target genes, 128 drug target pathways]

Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 70 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada